The Inflation Reduction Act (IRA) is setting new benchmarks for pharmaceutical pricing through Medicare's maximum…
Richard ChumbleyApril 1, 2025
Insights
Explore our articles, audio-visual presentations, and scientific insights
Our scientific teams are committed to thought leadership and we regularly develop insights, webinars, and conference presentations to support knowledge-sharing within the industry. Contact us with any questions or to request slide decks.
In a recent publication, David W. Miller shares why the traditional drug development model is no longer sustainable
Meet Ki Park, Vice President of Market Access Strategy and Analytics, as he discusses his journey into, and passion for, navigating US analytics
Download in-depth analysis of RPR-powered payer research into how the IRA’s maximum fair prices are reshaping the market.
Read David W. Miller’s article: ‘2025 Outlook: Key Trends Reshaping Life Sciences & Healthcare’
Audio-visual presentations
Discover how Genesis Research Group 'Innovates differently'
CEO David W. Miller explains what we mean when we say we help our life science clients to ‘Innovate differently’ and transform the way they engage with research partners.
Explore how evidence based pricing can inform global strategic launch decisions
Adam Weston explores how a data-driven, evidence-based pricing approach can inform strategic launch decisions and align clinical evidence with payer expectations, using Aduhelm and Leqembi as both cautionary tales and success stories.
Shining the light on vaccine market access
In March 2024, Genesis Research Group’s Katrin Nather and Tijana Ignjatovic presented at World EPA Congress on the subject of ‘Shining the light on vaccine market access’. Discover our RPR-powered access and pricing capabilities.
ITN Business interviews CEO David W. Miller
ITN Business invited Genesis Research Group to contribute to a news style programme ‘Advancing Healthcare’ featuring key opinion leaders in the healthcare industry talking about how best to confront its challenges.
Fit-for-purpose matchmaking
Earlier in 2024, our webinar ‘Fit-for-purpose matchmaking: a data selection and RWE approach for both regulatory and HTA audiences’ took place with Allie Sosinsky, Director, Pharmacoepidemiology and Safety, and Carole Longson MBE, Professor and Independent Senior Advisor. Explore our RWE expertise.
An introduction to the Flexible Integrated Team (FIT) engagement model
Our unique Flexible Integrated Team (FIT) engagement model represents a paradigm shift in how companies engage with a pharmaceutical, biotech and medical device research partners. Find out more.
Accelerating the generation of payer insights and evidence
Priti Jhingran and Tijana Ignjatovic present a HealthEconomics.com webinar describing how actionable payer insights facilitate an informed approach to evidence generation that is meaningful to payer, HTA, and medical decision-makers. Read more about RPR.
External control arms for regulatory and HTA agencies
In May 2023, Jen Wogen and Craig S. Parzynski presented at ISPOR 23 on ‘Developing Fit-for-Purpose External Control Arms to Optimize Submissions to Regulatory and Health Technology Assessment Agencies.’ Discover our ECA and RWE capabilities.
Stakeholder validation of evidence generation plans
At the World EPA Congress in March 2023, VP, Evidence Strategy Priti Jhingran delivered a presentation on ‘Stakeholder Validation of Evidence Generation Plans (EGPs) to Achieve Optimal Access’. Read more about stakeholder insights.
An introduction to our stakeholder engagement platform
RPR provides robust, transparent, survey-based stakeholder engagement in a fraction of the time and cost of traditional methods, plus the ability to ask participants clarificatory and follow-up questions. Read about RPR.
Envision Analogue - an introduction
An interview with Executive Director Tijana Ignjatovic regarding Envision, a platform that provides forward-looking evaluations and comprehensive strategic direction for market access viability after an oncology product has received positive EMA or FDA guidance. Download our Envision brochure.
Read our CEO’s contribution to the October issue of Life Science Leader
Efficiency Is The New Normal by David W. Miller, Ph.D, CEO,
Genesis Research Group
Read our external control arm contribution to the July/August issue of ISPOR’s Value & Outcomes Spotlight
The Role of External Control Arms in Drug Development and Considerations for Success by Alexandra Z. Sosinsky, Craig S. Parzynski, and Deborah Casso
Read HealthEconomics.com’s exclusive interview with our CEO, David W. Miller on ‘Innovating Differently’
Featured articles
Kuldeep Singh et al
Communicating therapy value to oncology clinical pathway developers
Download white paperArticles
Allowable for the first time due to the Inflation Reduction Act, the Centers for Medicare…
Richard ChumbleySeptember 12, 2024
The Evidence Base recently featured a 'deep dive' analysis of this ISPOR 2024 presentation. …
Richard ChumbleyJune 6, 2024
Tijana Ignjatovic, MA, PhD, Executive Director, Access & Pricing, applies the case study of Minjuvi…
Richard ChumbleyMay 31, 2024
Andy Surinach, Executive Director of RWE and Data Strategy, delves into recent breakthroughs in Parkinson's…
Richard ChumbleyApril 15, 2024
AMCP Nexus 2023, held recently in Orlando, Florida, hosted a forum for healthcare stakeholders to…
Richard ChumbleyNovember 2, 2023
Alexandra Sosinsky, our Director, Pharmacoepidemiology & Safety, offers her thoughts on FDA’s recent guidance regarding…
Richard ChumbleyOctober 11, 2023
Catherine Tak Piech argues that specialists and a plethora of new technologies are now well…
Casey FrushourJanuary 19, 2022
Sign up to receive regular thought leadership articles and videos, plus the latest RWE, HEOR, and market access trends
Sign up for our Newsletter
Headquarters:
HOBOKEN
111 River Street, Suite 1120
Hoboken, New Jersey 07030, US
